BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 14, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Grey Wolf raises $49M to advance tumor drug toward phase I/II

Jan. 26, 2023
By Caroline Richards
An anticancer approach that leads to improved tumor visibility edged closer to the clinic after Grey Wolf Therapeutics Ltd. scooped $49 million in a series B round. The Oxford, U.K.-based immuno-oncology company plans to use the proceeds to move its lead candidate, GRWD-5769, into a phase I/II trial.
Read More

Financings for Jan. 26, 2023

Jan. 26, 2023
Med-tech firms raising money in public or private financings, including: Alleviant Medical.
Read More

Financings for Jan. 26, 2023

Jan. 26, 2023
Biopharmas raising money in public or private financings, including: Genelux, Harbour, HBN, Hemogenyx, Iaso, Inhibikase, Panbela, Tetra.
Read More

Cadrenal closes on 2023’s first US IPO

Jan. 25, 2023
By Lee Landenberger
Coming off a tough year for raising money, Cadrenal Therapeutics Inc. is leading the charge into a new year by completing 2023’s first U.S. IPO. The company closed its IPO of 1.4 million shares at $5 each for $7 million. The stock (NASDAQ:CVKD) began trading Jan. 20 and closed 9.37% downward on Jan. 25 at $2.90 per share.
Read More

Financings for Jan. 25, 2023

Jan. 25, 2023
Med-tech firms raising money in public or private financings, including: Miach Orthopaedics.
Read More

Financings for Jan. 25, 2023

Jan. 25, 2023
Biopharmas raising money in public or private financings, including: Atomic, Deciphera, Jasper, Myosana, Oxurion, Precigen, Pliant, Rewind, Verastem.
Read More
Heart scientific overlay

Core Medical completes series C round to develop artificial heart

Jan. 24, 2023
By Doris Yu
Shenzhen Core Medical Technology Co. Ltd. completed a series C round to speed up the development of its left ventricular assist devices (LVAD) for heart failure.
Read More

Financings for Jan. 24, 2023

Jan. 24, 2023
Med-tech firms raising money in public or private financings, including: Endosound, Julier Medical.
Read More

Financings for Jan. 24, 2023

Jan. 24, 2023
Biopharmas raising money in public or private financings, including: Apexigen, Cymabay, Pliant.
Read More

Financings for Jan. 23, 2023

Jan. 23, 2023
Med-tech firms raising money in public or private financings, including: Deciphex, Ferronova, Julier Medical, Renew, Waire Health.
Read More
Previous 1 2 … 303 304 305 306 307 308 309 310 311 … 664 665 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing